This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent. Top assignee: Shanghaitech University. Active years: 2023-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2025
Title: Qianqian Yin: Innovator in Targeted Protein Degradation
Introduction
Qianqian Yin is a prominent inventor based in Shanghai, China. She has made significant contributions to the field of targeted protein degradation, particularly in the context of anti-tumor applications. With a total of two patents to her name, her work is paving the way for innovative treatments in oncology.
Latest Patents
Qianqian Yin's latest patents focus on compounds that target and degrade specific proteins associated with tumors. One of her notable patents involves compounds of formula (I) that demonstrate anti-tumor uses. These compounds consist of three parts: a small molecule compound (SMBP) that binds to a protein, a linker (LIN), and a ubiquitin ligand (ULM). The designed compounds exhibit a wide range of pharmacological activities, including the ability to degrade specific proteins and inhibit their activities, making them valuable in tumor treatments. Another patent addresses compounds targeting and degrading the BCR-ABL protein, which is crucial in certain cancers. This compound also comprises four moieties, including a BCR-ABL tyrosine kinase inhibitor and a small molecule ligand for proteases. The pharmacological effectiveness of these compounds highlights their potential in treating relevant tumors.
Career Highlights
Qianqian Yin is affiliated with Shanghaitech University, where she continues her research and development in the field of targeted therapies. Her innovative work has garnered attention in the scientific community, contributing to advancements in cancer treatment.
Collaborations
Qianqian collaborates with notable colleagues, including Xiaobao Yang and Biao Jiang. Their combined expertise enhances the research efforts in developing effective anti-tumor compounds.
Conclusion
Qianqian Yin's contributions to the field of targeted protein degradation represent a significant advancement in cancer research. Her innovative patents and collaborations are paving the way for new therapeutic options in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile